THERAPIX BIOSCIENCES LTD.
Code of Business Ethics
Ethics are important to Therapix Biosciences Ltd. (together with its subsidiaries, “Therapix”) and its directors, officers and employees (each an” Associate”). Therapix is committed to the highest ethical standards and to conducting its business with the highest level of integrity.
The Therapix Code of Business Conduct and Ethics (the “Code”) has four primary functions:
- To establish and clearly communicate our standards of business conduct, our ethical principles and our expectations;
- To ensure that business policies and practices continue to be aligned with those standards and principles;
- To establish responsibility for monitoring compliance; and
- To set forth the manner in which perceived violations of ethical principles are to be reported.
The Code applies to all Associates.
Therapix is committed to the ideals of uncompromising honesty and integrity. All Therapix Associates are expected to adhere to the highest standards of ethics; to be honest and ethical in dealing with each other, with shareholders and with customers, vendors and all other third parties. All Therapix Associates must respect the rights of fellow Associates and third parties. All actions must be free from discrimination, libel, slander or harassment. Each person must be accorded equal opportunity, regardless of age, race, sex, sexual preference, color, creed, religion, national origin, marital status, veteran’s status, handicap or disability. Misconduct (any violation of this Code) will be addressed as it is identified with appropriate disciplinary action. Misconduct cannot be excused because it was directed or requested by another. All Therapix Associates are expected to alert management whenever an unethical, dishonest or illegal act is discovered or suspected, as further provided for in this Policy. The following areas frequently give rise to ethical concerns. A violation of the standards contained in this Code will result in corrective action, including possible dismissal.
Should any Therapix Associate have any questions concerning this Policy, please direct them to the Chief Financial Officer of Therapix (the “CFO”).
The CFO may consult outside counsel with respect to any issue relating to this Policy.
3. Conflicts of Interest
Conflicts of interest arise whenever actions are based on interests other than those of Therapix.
All Therapix Associates must avoid any personal activity, investment or association that may interfere with using good judgment concerning Therapix’s best interests.
No Therapix Associate may not exploit his or her position or relationship with Therapix for personal gain.
All Therapix Associates should avoid even the appearance of such a conflict. For example, a conflict of interest may arise if:
- An Associate causes Therapix to engage in business transactions with relatives or friends;
- An Associate uses information of Therapix, a customer or supplier for your own personal gain, or the personal gain of relatives or friends;
- An Associate have a financial interest in Therapix’s customers, suppliers or competitors;
- An Associate receives a loan or guarantee of obligations, from Therapix or from a third party, as a result of his position at Therapix; or
- An Associate competes, or prepares to compete, with Therapix while still employed by it.
Employees who are involved in or are aware of a transaction involving any of the relationships described above, must report the transaction to the CFO. Directors and officers shall report such transactions to the Chairman of Therapix’s Audit Committee. All transactions between Therapix and any employee or member of the Associate’s immediate family, or any entity in which such employee or a member of his or her immediate family has a significant financial interest, must be approved by the CFO. Transactions described in the previous sentence between Therapix and any director or officer or member of such person’s immediate family, or any entity in which such person or member of his or her immediate family has a significant financial interest, must be approved by the Board of Directors.
There may be other situations in which a conflict of interest may arise. If an Associate has any questions or concerns about any situation, he or she should follow the guidance outlined in the section below on Reporting Ethical Violations.
4. Public Reporting of Financial and Non-financial Information
Therapix is a publicly traded company in the U.S. and thus, subject to the Securities Act of 1933, the Securities Exchange Act of 1934 and numerous other laws, rules and regulations promulgated thereunder (the “Securities Laws”). The U.S. Securities and Exchange Commission
(the “SEC”) requires companies to maintain disclosure controls and procedures designed to ensure that information required by the Securities Laws to be disclosed by publicly held companies is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. It is, therefore, imperative that all disclosures contained in Therapix’s public filings and other public communications are full, fair, accurate, timely and understandable.
Every Associate who participates in the information gathering process for Therapix’s public filings and other public communications is responsible for the timeliness and accuracy of the information contained therein. Those persons having responsibility for particular areas of Therapix’s periodic reports such as the Form 20-F and the Form 6-K (if any) must report to the Board on an ongoing basis the following matters which come to their attention:
- Deviations from or changes to the current public information available for Therapix;
- Changes in risks, or new risks, to Therapix as they are identified; and Changes that may affect Therapix’s financial results.
- Therapix may establish a separate Disclosure Policy that may provide who may communicate information to the press and the financial analyst community.
All Therapix Associates should review Therapix’s Disclosure Policy and discuss all questions that they may have with the CFO.
Our employees who work in the Financial Department hold an important and elevated role in corporate governance. They are empowered to ensure that shareholder interests are appropriately balanced, protected and preserved. Accordingly, all financial managers are expected to uphold the following standards:
- To provide information that is accurate, complete, objective, relevant, timely and understandable;
- To comply with laws, rules and regulations of federal, state, provincial and local governments, and appropriate regulatory agencies;
- To act in good faith, responsibly, with due care, competence and diligence, without misrepresenting facts or allowing their independent judgment to be subordinated;
- To respect the confidentiality of information acquired in connection with their activities for Therapix, except when authorized or otherwise legally obligated to disclose;
- To share knowledge and to maintain skills needed to perform their jobs;
- To proactively promote ethical behavior as a responsible partner among peers in the workplace and community; and
- To achieve responsible use of and control over all assets and resources employed by or entrusted to them.
Compliance with all governmental laws, rules and regulations applicable to Therapix is mandatory and any violations thereof are considered violations of this Code. Mistakes should never be covered up, but should be immediately fully disclosed and corrected, if possible.
All Therapix Associates that have any questions about their duties with regard to public reporting should ask the CFO.
5. Bribes and Kickbacks
A kickback or bribe includes any item intended to improperly obtain favorable treatment. Other than for modest gifts given or received in the normal course of business (e.g., coffee mugs, pens and other logoed promotional materials or business lunches), neither you nor your relatives may give gifts to, or receive gifts from, Therapix’s customers and suppliers. Other gifts may be given or accepted only with prior approval of the CFO. In no event should you put Therapix or yourself in a position that would be uncomfortable if knowledge of the gift was made public. Dealing with government employees is often different than dealing with private persons. Many governmental bodies strictly prohibit the receipt of any gratuities by their employees, including meals and entertainment. All Therapix associates must be aware of and strictly follow these prohibitions.
6. Conducting Business Outside of the United States and the Foreign Corrupt Practices Act
Therapix has an international presence and thus, certain Associates or other affiliates of the company may find it necessary to interact with foreign governments or officials in the furtherance of Therapix’s business activities. In any dealings with foreign officials, candidates, or political parties, Therapix and its Associates, consultants, agents, subsidiaries, distributors, resellers and representatives, must comply with the following policy.
Generally, Therapix policies, the U.S. Foreign Corrupt Practices Act (“FCPA”), and applicable foreign laws prohibit payments to, and business relationships with, government officials (“government officials” may include employees of entities that are state owned, in whole or part, public international organizations and political parties or political candidates) that could be construed as bribes or attempts to influence government behavior.
All Therapix Associates may not give, offer, promise, or authorize direct or indirect payments to foreign officials for the purpose of obtaining or retaining business for Therapix. Payments include money, gifts, or anything of value, and need not actually be delivered, but merely have been intended for a corrupt purpose, to violate the FCPA.
It is therefore illegal and against Therapix policy for any Associate or other Therapix representative to offer or give anything of value that is intended to:
- influence any act or decision of a foreign official in his or her official capacity;
- induce the official violate a lawful duty of his position or to use his influence improperly; or
- obtain an improper advantage for Therapix.
Therapix and individuals may face significant civil and criminal punishment in both the United States and in other countries, including imprisonment, for violating the FCPA and local laws.
Acknowledging that in certain foreign localities, payments to local government officials may be customary to expedite processes such as the granting of a business license or similarly routine governmental action, the FCPA contains a narrow exception for such payments.
In every case, prior to making, promising, or offering any such payment, any Associate or affiliate of Therapix must consult with the CFO should uncertainties arise. Furthermore, if it is determined that a payment meets this narrow exception, it must be recorded accurately by the accounting department, as it is an independent violation of the FCPA to mischaracterize any such payment in the financial records. Both the consultation with the CFO and the accounting treatment of the payment must be documented in writing.
7. Quality and Regulatory Compliance
Therapix is subject to numerous international, federal and state laws concerning the design, clinical development, manufacture, distribution and promotion of its products. The Federal Food, Drug, and Cosmetic Act (the “FDC Act”) is the primary regulatory statute governing Therapix’s activities. The FDC Act is implemented by the U.S. Food and Drug Administration (the “FDA”) through the promulgation of regulations and by the issuance of guidelines and other informal notices regarding compliance requirements.
FDA regulations applicable to medical devices, biologics and pharmaceuticals encompass a wide variety of activities including: product clearance; labeling, advertising, and promotion; reporting requirements; establishment registration and product listing; current good manufacturing practices; and preclinical studies and clinical studies. Other federal agencies also have applicable laws, regulations and guidelines, as do individual state governments.
Therapix has established policies and procedures to ensure that our activities are conducted in compliance with the federal and state laws and regulations pertaining to FDA-regulated products.
In addition to legal compliance, Therapix Associates are required to maintain the highest ethical and scientific standards in researching and developing Therapix’s products.
Associates are further required to be scrupulously accurate in data submitted to FDA, publications, or any other party. You will adhere to all standards and procedures necessary to ensure rigorous scientific inquiry and will interact with federal and state agencies in a forthright manner designed to ensure the safe and effective use of its products. Additionally, in accordance with Therapix’s objective, Associates are required to manufacture Therapix’s products in a manner designed to ensure their safety, integrity, and suitability for patients, and to market and sell its products in an honest and balanced manner that provides health professionals with the information necessary to use its products appropriately.
Clinical studies will be conducted in such a fashion as to safeguard the welfare of subjects and ensure the scientific integrity of the research.
Associates will maintain accurate and complete records of all data related to FDA-regulated products in order to comply with FDA regulations. This work includes research and development, preclinical and clinical studies, manufacturing, marketing, quality control and quality assurance, regulatory and other activities as determined by our Chief Executive Officer (“CEO”).
As part of Therapix’s quality system, Associates are required to maintain reliable documentation. The accuracy of data in our records, including full disclosure, lack of material omission, and integrity of the data is your priority.
Any Associate who alters or falsifies data, destroys or fails to maintain product related data, or omits data from records that are needed to provide full information regarding a commercial or development stage product is acting in violation of this Code.
In case of any questions related to quality and regulatory compliance, you should consult with your supervisor, or the head of Quality/Regulatory departments.
8. Improper Use or Theft of Therapix Property
Every Associate must safeguard Therapix property from loss or theft, and may not take such property for personal use. Therapix property includes such items as biological materials, chemicals, laboratory equipment and machinery, inventory, vehicles, software, computers, office equipment, and supplies as well as confidential information such as non-public personal information about customers, customer lists, and proprietary product information, to name a few.
You must appropriately secure all Therapix property within your control to prevent its unauthorized use.
9. Fair Dealing
No Therapix Associate should take unfair advantage of anyone through manipulation, abuse of privileged information, misrepresentation of facts, or any other unfair-dealing practice.
10. Fair Competition and Antitrust Laws
Therapix must comply with all applicable fair competition and antitrust laws. These laws attempt to ensure that businesses compete fairly and honestly and prohibit conduct seeking to reduce or restrain competition. If you are uncertain whether a contemplated action raises unfair competition or antitrust issues, you should raise the issue with the CFO.
11. Insider Trading
If an Associate has material non-public information relating to Therapix, it is our policy that neither that person (nor any of his/her relatives) may buy or sell any Therapix securities or engage in any other action to take advantage of, or pass on to others, that information. This policy also applies to information relating to any other company, including our customers, partners or suppliers, obtained in the course of employment. Officers, directors and employees should carefully review and comply with Therapix’s separate Insider Trading Policy, if and when such policy is adopted. Questions regarding insider trading should be addressed to the CFO.